Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Minerva Anestesiol ; 86(4): 433-444, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-31818084

RESUMEN

Advantages of propofol use in children may include less airway complications, less emergence agitation, and less postoperative behavioral changes. However, needle phobia and the complexity of total intravenous anesthesia set-up, as well as the pharmacokinetic and pharmacodynamic restrictions may limit the wide use of propofol-based anesthesia in the form of total intravenous anesthesia. Furthermore, pediatric infusion models and monitoring techniques are not fully validated yet. The choice of anesthesia type in children seems to be the result of a complex interplay between many factors related to the patient and the provider as well as logistic and operational factors that contribute to the decision-making process. Propofol has earned its place as a valuable choice in pediatric anesthesia. In addition, propofol and inhalation anesthesia should not be looked at as mutually exclusive; a combination of both may sometimes be the best approach to complex clinical dilemmas.


Asunto(s)
Anestesia por Inhalación , Hipnóticos y Sedantes , Propofol , Anestesia General , Niño , Humanos , Hipnóticos y Sedantes/uso terapéutico , Propofol/uso terapéutico
2.
Curr Opin Obstet Gynecol ; 20(3): 313-9, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18460948

RESUMEN

PURPOSE OF REVIEW: Worldwide 50-80 million people suffer from infertility. Assisted reproductive technology has provided a way of overcoming infertility and childlessness. The current article will focus on data linking infertility and its treatment to ovarian cancer. RECENT FINDINGS: Ovarian cancer risks associated with fertility drug treatment are encouraging, but not decisive. In view of the limited ability to evaluate drug effects on borderline tumors, given their rare occurrence, studies involving patient reports of prior drug exposures have noted an elevated risk of borderline tumors associated with fertility drugs. Nevertheless, the risk of invasive ovarian cancer appears to be restricted to those women who remain childless despite the infertility treatment. SUMMARY: As long as doubt persists, it might be advisable to reflect on a few clinical recommendations: identify high-risk infertile patients for ovarian cancer, investigate preexisting cancer before fertility treatment, inform patients regarding potential risks, obtain an informed consent, avoid exposure to long periods of ovulation induction cycles that are given before patients are referred for in-vitro fertilization and embryo transfer for women at greater risk and monitor women who have been treated with these drugs, especially those who failed to conceive, regularly and thoroughly.


Asunto(s)
Fármacos para la Fertilidad Femenina/efectos adversos , Neoplasias Ováricas/inducido químicamente , Femenino , Humanos , Estudios Retrospectivos , Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA